Cancer is among the leading causes of death in the US today, with breast, prostate, lung and colon cancers being the most prevalent. The optimal cancer treatment modality is one that restores and stimulates the normal immunological responses against an undesirable growth.  Immunophotonics is developing inCVAX, an innovative, practical, and safe therapeutic cancer vaccine that has shown very encouraging initial results in the treatment of metastatic cancer.

• inCVAX stimulates the patient's immune system to fight back against cancer
• inCVAX is minimally invasive and no signs of toxicity have been observed
• inCVAX may eliminate treated primary tumors and untreated metastases
• inCVAX has the potential to induce long-term immunity and survival
• Over 10 years of research & 100 peer-review papers support the inCVAX approach
• A strong team of experience & dedicated advisors

Immunophotonics Inc is a US-based research-oriented company in the frontline of cancer vaccine research. Our main objective is to develop and introduce Laser-Assisted Immunotherapy, which is an in situ cancer vaccine (inCVAX), one of the most innovative and promising modalities for metastatic tumors to have emerged in the cancer research world.